These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29482389)

  • 21. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
    Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
    Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
    Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors.
    Li Y; Chang Y; Fu J; Ding R; Zhang L; Liang T; Liu Y; Liu Y; Hu J
    Eur J Med Chem; 2021 Dec; 226():113845. PubMed ID: 34534838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
    AboulWafa OM; Daabees HMG; Badawi WA
    Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of novel Thiazolo[5,4-b]pyridine derivatives as potent and selective EGFR-TK inhibitors targeting resistance Mutations in non-small cell lung cancer.
    Borude AS; Deshmukh SR; Tiwari SV; Kumar SH; Thopate SR
    Eur J Med Chem; 2024 Oct; 276():116727. PubMed ID: 39094428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction.
    Nemr MTM; Elshewy A; Ibrahim ML; El Kerdawy AM; Halim PA
    Bioorg Chem; 2024 Sep; 150():107566. PubMed ID: 38896936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and in vitro antitumor evaluation of new thieno[2,3-d]pyrimidine derivatives as EGFR and DHFR inhibitors.
    Fouad MM; Ghabbour HA; Shehata IA; El-Ashmawy MB
    Bioorg Chem; 2024 Jul; 148():107401. PubMed ID: 38749115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines.
    Salem MSH; Abdel Aziz YM; Elgawish MS; Said MM; Abouzid KAM
    Bioorg Chem; 2020 Jan; 94():103472. PubMed ID: 31813475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
    El-Metwally SA; Abou-El-Regal MM; Eissa IH; Mehany ABM; Mahdy HA; Elkady H; Elwan A; Elkaeed EB
    Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
    Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
    Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
    Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Novel Class of Phenylpyrazolo[3,4-
    Aljohani AKB; El Zaloa WAZ; Alswah M; Seleem MA; Elsebaei MM; Bayoumi AH; El-Morsy AM; Almaghrabi M; Awaji AA; Hammad A; Alsulaimany M; Ahmed HEA
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eco-friendly Synthesis of Pyrido[2,3-d]pyrimidine Analogs and Their Anticancer and Tyrosine Kinase Inhibition Activities.
    El-Naggar AM; Khalil AK; Zeidan HM; El-Sayed WM
    Anticancer Agents Med Chem; 2017; 17(12):1644-1651. PubMed ID: 28403776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.